Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xenon Pharmaceuticals

Explore full profile

From families to genes, from genes to drugs.

Burnaby, CanadaFounded 1996Biotech & Life Sciences
Valuation $4.97B Market cap · 2026
Revenue $7.5M Latest reported FY
Total funding $50–100M Disclosed equity funding

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address neurological disorders. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as epilepsy and other central nervous system disorders. Xenon's business model revolves around the research, development, and commercialization of novel therapies. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The company serves a diverse client base, including healthcare providers, patients, and research institutions. Xenon leverages its expertise in genetics and neurology to create a robust pipeline of drug candidates, currently highlighted by its Phase 2 proof of concept study for XEN007 in pediatric patients with treatment-resistant childhood absence epilepsy (CAE). The company's strategic focus on unmet medical needs and its commitment to advancing neurology therapies position it as a key player in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Founded
1996
Headquarters
Burnaby, Canada
Listing
IPO 2014
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Latest news

Press, funding announcements and product moves mentioning Xenon Pharmaceuticals.

See all news

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Series B and later2 investors entered at this stage

  • Northview LifeSciences
  • Neurocrine Biosciences
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States49.2%
🇨🇦 Canada48.5%
🇵🇰 Pakistan1.3%
🇦🇺 Australia0.3%
🇰🇷 South Korea0.3%
Top 5 of 6 shown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States54.3%
🇨🇦 Canada25.2%
🇬🇧 United Kingdom7%
🇵🇭 Philippines4.3%
🇮🇳 India3.5%
Top 5 markets shown

Patents

Estimated portfolio value
$90M

68 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xenon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xenon Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.